Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study

Regulatory Toxicology and Pharmacology

Volumn 81, Issue , 2016, Pages 212-222

  Chouinard, Luc ^a   Felx, Melanie ^a   Mellal, Nacera ^a   Varela, Aurora ^a   Mann, Peter ^b   Jolette, Jacquelin ^a   Samadfam, Rana ^a   Smith, Susan Y ^a   Locher, Kathrin ^c   Buntich, Sabina ^c   Ominsky, Michael S ^c   Pyrah, Ian ^c   Boyce, Rogely Waite ^c  

^a CHARLES RIVER LABORATORIES   (United States)

^b EPL Northwest   (United States)

^c AMGEN INC   (United States)

Author keywords

Carcinogenicity; Chronic toxicity; Null antibody; Romosozumab; Sclerostin antibody

Indexed keywords

ROMOSOZUMAB; SCLEROSTIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CANCER INCIDENCE; CARCINOGENICITY; CHRONIC TOXICITY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOGENICITY; LOSS OF FUNCTION MUTATION; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RISK ASSESSMENT; WNT SIGNALING PATHWAY; ANIMAL; CARCINOGEN TESTING; CHEMICALLY INDUCED; DOSE RESPONSE; MOUSE; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOGENICITY TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; NEOPLASMS; RATS; RISK ASSESSMENT;

EID: 84985993381     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2016.08.010     Document Type: Article

References (51)

1. Anastas, J.N., Moon, R.T., WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13 (2013), 11–26.
2. Andrews, E.B., Gilsenan, A.W., Midkiff, K., Sherrill, B., Wu, Y., Mann, B.H., Masica, D., The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J. Bone Min. Res. 27 (2012), 2429–2437.
3. Bailer, A.J., Portier, C.J., Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 44 (1988), 417–431.
4. Baron, R., Hesse, E., Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J. Clin. Endocrinol. Metab. 97 (2012), 311–325.
5. Baron, R., Kneissel, M., WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19 (2013), 179–192.
6. Bieler, G.S., Williams, R.L., Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity. Biometrics 49 (1993), 793–801.
7. Bradbury, J.M., Edwards, P.A., Niemeyer, C.C., Dale, T.C., Wnt-4 expression induces a pregnancy-like growth pattern in reconstituted mammary glands in virgin mice. Dev. Biol. 170 (1995), 553–563.
8. Chouinard L., Felx M., Mellal N., Varela A., Mann P., Jolette J., Samadfam R., Smith S.Y., Locher K., Buntich S., Ominsky M.S., Pyrah I. and Boyce R.W., Chronic toxicity studies in rats and monkeys support bone-specific effects of romosozumab with no evidence of histopathologic risk factors for neoplasia, Regul. Toxicol. Pharmacol. Submitted, (Data in Brief).
9. Fox, J., Miller, M.A., Newman, M.K., Metcalfe, A.F., Turner, C.H., Recker, R.R., Smith, S.Y., Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif. Tissue Int. 79 (2006), 262–272.
10. Gesty-Palmer, D., Yuan, L., Martin, B., Wood, W.H. 3rd, Lee, M.H., Janech, M.G., Tsoi, L.C., Zheng, W.J., Luttrell, L.M., Maudsley, S., Beta-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol. Endocrinol. 27 (2013), 296–314.
11. Gong, J., Cao, J., Ho, J., Chen, C., Paszty, C., Romosozumab blocks the binding of sclerostin to the two key Wnt signaling co-receptors, LRP5 and LRP6, but not to LRP4. Annual Meeting of ASBMR, Atlanta, GA, 2016.
12. Hall, A.P., Escott, K.J., Sanganee, H., Hickling, K.C., Preclinical toxicity of AZD7969: effects of GSK3beta inhibition in adult stem cells. Toxicol. Pathol. 43 (2015), 384–399.
13. Harris, D., Gilsenan, A., Harding, A., Andrews, E., Kellier, N., Masica, D., Long-term Cancer surveillance: five-year update for the Forteo patient Registry surveillance study. Pharmacoepidemiol Drug Saf. 24 (2015), 547–548.
14. Hoeppner, L.H., Secreto, F.J., Westendorf, J.J., Wnt signaling as a therapeutic target for bone diseases. Expert Opin. Ther. Targets 13 (2009), 485–496.
15. ICH, International Conference on Harmonisation. Proposed Change to Rodent Carcinogenicity Testing of Pharmaceuticals - Regulatory Notice Document. S1. 2015 (accessed 26.05.16.) http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S1/S1_Concept_Paper_14_November_2012.pdf.
16. Jiang, Y., Zhao, J.J., Mitlak, B.H., Wang, O., Genant, H.K., Eriksen, E.F., Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Min. Res. 18 (2003), 1932–1941.
17. Jolette, J., Varela, A., Attalla, B., Smith, S.Y., Hattersley, G., Comparing the incidence of bone tumors in rats chronically exposed to abaloparatide (BA058) or PTH. Annual Meeting of the American Society for Bone and Mineral Research, Houston, TX, 2014.
18. Jolette, J., Wilker, C.E., Smith, S.Y., Doyle, N., Hardisty, J.F., Metcalfe, A.J., Marriott, T.B., Fox, J., Wells, D.S., Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol. Pathol. 34 (2006), 929–940.
19. Jones, K.B., Osteosarcomagenesis: modeling cancer initiation in the mouse. Sarcoma, 2011, 2011, 694136.
20. Kansara, M., Tsang, M., Kodjabachian, L., Sims, N.A., Trivett, M.K., Ehrich, M., Dobrovic, A., Slavin, J., Choong, P.F., Simmons, P.J., Dawid, I.B., Thomas, D.M., Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Investig. 119 (2009), 837–851.
21. Lane, T.F., Leder, P., Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 15 (1997), 2133–2144.
22. Lengner, C.J., Steinman, H.A., Gagnon, J., Smith, T.W., Henderson, J.E., Kream, B.E., Stein, G.S., Lian, J.B., Jones, S.N., Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J. Cell Biol. 172 (2006), 909–921.
23. Lewiecki, E.M., Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther. Adv. Musculoskelet. Dis. 6 (2014), 48–57.
24. Li, X., Liu, H., Qin, L., Tamasi, J., Bergenstock, M., Shapses, S., Feyen, J.H., Notterman, D.A., Partridge, N.C., Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J. Biol. Chem. 282 (2007), 33086–33097.
25. Li, X., Niu, Q.T., Warmington, K.S., Asuncion, F.J., Dwyer, D., Grisanti, M., Han, C.Y., Stolina, M., Eschenberg, M.J., Kostenuik, P.J., Simonet, W.S., Ominsky, M.S., Ke, H.Z., Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology 155 (2014), 4785–4797.
26. Li, X., Ominsky, M.S., Warmington, K.S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., Chen, Q., Winters, A., Boone, T., Geng, Z., Niu, Q.T., Ke, H.Z., Kostenuik, P.J., Simonet, W.S., Lacey, D.L., Paszty, C., Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Min. Res. 24 (2009), 578–588.
27. Li, X., Warmington, K.S., Niu, Q.T., Asuncion, F.J., Barrero, M., Grisanti, M., Dwyer, D., Stouch, B., Thway, T.M., Stolina, M., Ominsky, M.S., Kostenuik, P.J., Simonet, W.S., Paszty, C., Ke, H.Z., Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J. Bone Min. Res. 25 (2010), 2647–2656.
28. Liu, H., Li, B., p53 control of bone remodeling. J. Cell Biochem. 111 (2010), 529–534.
29. McClung, M.R., Grauer, A., Boonen, S., Bolognese, M.A., Brown, J.P., Diez-Perez, A., Langdahl, B.L., Reginster, J.-Y., Zanchetta, J.R., Wasserman, S.M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., Bone, H.G., Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370 (2014), 412–420.
30. Nioi, P., Taylor, S., Hu, R., Pacheco, E., He, Y.D., Hamadeh, H., Paszty, C., Pyrah, I., Ominsky, M.S., Boyce, R.W., Transcriptional profiling of laser capture microdissected subpopulations of the osteoblast lineage provides insight into the early response to sclerostin antibody in rats. J. Bone Min. Res. 30 (2015), 1457–1467.
31. Nusse, R., Varmus, H.E., Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31 (1982), 99–109.
32. Ominsky, M.S., Li, C., Li, X., Tan, H.L., Lee, E., Barrero, M., Asuncion, F.J., Dwyer, D., Han, C.Y., Vlasseros, F., Samadfam, R., Jolette, J., Smith, S.Y., Stolina, M., Lacey, D.L., Simonet, W.S., Paszty, C., Li, G., Ke, H.Z., Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J. Bone Min. Res. 26 (2011), 1012–1021.
33. Ominsky, M.S., Libanati, C., Niu, Q.T., Boyce, R.W., Kostenuik, P.J., Wagman, R.B., Baron, R., Dempster, D.W., Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J. Bone Min. Res. 30 (2015), 1280–1289.
34. Ominsky, M.S., Vlasseros, F., Jolette, J., Smith, S.Y., Stouch, B., Doellgast, G., Gong, J., Gao, Y., Cao, J., Graham, K., Tipton, B., Cai, J., Deshpande, R., Zhou, L., Hale, M.D., Lightwood, D.J., Henry, A.J., Popplewell, A.G., Moore, A.R., Robinson, M.K., Lacey, D.L., Simonet, W.S., Paszty, C., Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Min. Res. 25 (2010), 948–959.
35. Padhi, D., Jang, G., Stouch, B., Fang, L., Posvar, E., Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Min. Res. 26 (2011), 19–26.
36. Peto, R., Pike, M.C., Day, N.E., Gray, R.G., Lee, P.N., Parish, S., Peto, J., Richards, S., Wahrendorf, J., Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr. Eval. Carcinog. Risk Chem. Hum.(Suppl. 2), 1980, 311–426.
37. Polakis, P., The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17 (2007), 45–51.
38. Poole, K.E., van Bezooijen, R.L., Loveridge, N., Hamersma, H., Papapoulos, S.E., Lowik, C.W., Reeve, J., Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19 (2005), 1842–1844.
39. Qin, L., Li, X., Ko, J.K., Partridge, N.C., Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J. Biol. Chem. 280 (2005), 3104–3111.
40. Reddy, M.V., Sistare, F.D., Christensen, J.S., Deluca, J.G., Wollenberg, G.K., Degeorge, J.J., An evaluation of chronic 6- and 12-month rat toxicology studies as predictors of 2-year tumor outcome. Vet. Pathol. 47 (2010), 614–629.
41. Roelink, H., Wagenaar, E., Lopes da Silva, S., Nusse, R., Wnt-3, a gene activated by proviral insertion in mouse mammary tumors, is homologous to int-1/Wnt-1 and is normally expressed in mouse embryos and adult brain. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 4519–4523.
42. Schett, G., Bozec, A., Removing the bone brake. Cell Metab. 20 (2014), 394–395.
43. Sistare, F.D., Morton, D., Alden, C., Christensen, J., Keller, D., Jonghe, S.D., Storer, R.D., Reddy, M.V., Kraynak, A., Trela, B., Bienvenu, J.G., Bjurstrom, S., Bosmans, V., Brewster, D., Colman, K., Dominick, M., Evans, J., Hailey, J.R., Kinter, L., Liu, M., Mahrt, C., Marien, D., Myer, J., Perry, R., Potenta, D., Roth, A., Sherratt, P., Singer, T., Slim, R., Soper, K., Fransson-Steen, R., Stoltz, J., Turner, O., Turnquist, S., van Heerden, M., Woicke, J., DeGeorge, J.J., An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol. Pathol. 39 (2011), 716–744.
44. Stolina, M., Dwyer, D., Niu, Q.T., Villasenor, K.S., Kurimoto, P., Grisanti, M., Han, C.Y., Liu, M., Li, X., Ominsky, M.S., Ke, H.Z., Kostenuik, P.J., Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone 67 (2014), 305–313.
45. Taylor, S., Ominsky, M.S., Hu, R., Pacheco, E., He, Y.D., Brown, D.L., Aguirre, J.I., Wronski, T.J., Buntich, S., Afshari, C.A., Pyrah, I., Nioi, P., Boyce, R.W., Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone 84 (2016), 148–159.
46. US FDA, Guidance for Industry: Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals. 2001 (accessed 26.05.16.) http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079272.pdf.
47. Vahle, J.L., Long, G.G., Sandusky, G., Westmore, M., Ma, Y.L., Sato, M., Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol. Pathol. 32 (2004), 426–438.
48. Vahle, J.L., Sato, M., Long, G.G., Young, J.K., Francis, P.C., Engelhardt, J.A., Westmore, M.S., Linda, Y., Nold, J.B., Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. 30 (2002), 312–321.
49. van Bezooijen, R.L., Roelen, B.A., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S.E., Ten Dijke, P., Lowik, C.W., Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199 (2004), 805–814.
50. Wang, X., Kua, H.Y., Hu, Y., Guo, K., Zeng, Q., Wu, Q., Ng, H.H., Karsenty, G., de Crombrugghe, B., Yeh, J., Li, B., p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J. Cell Biol. 172 (2006), 115–125.
51. Watanabe, A., Yoneyama, S., Nakajima, M., Sato, N., Takao-Kawabata, R., Isogai, Y., Sakurai-Tanikawa, A., Higuchi, K., Shimoi, A., Yamatoya, H., Yoshida, K., Kohira, T., Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). J. Toxicol. Sci. 37 (2012), 617–629.